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ABSTR ACT: Dynamic contrast-enhanced perfusion and permeability imaging, using computed tomography and magnetic resonance systems, are 
important techniques for assessing the vascular supply and hemodynamics of healthy brain parenchyma and tumors. These techniques can measure 
blood flow, blood volume, and blood–brain barrier permeability surface area product and, thus, may provide information complementary to clinical and 
pathological assessments. These have been used as biomarkers to enhance the treatment planning process, to optimize treatment decision-making, and 
to enable monitoring of the treatment noninvasively. In this review, the principles of magnetic resonance and computed tomography dynamic contrast-
enhanced perfusion and permeability imaging are described (with an emphasis on their commonalities), and the potential values of these techniques for 
differentiating high-grade gliomas from other brain lesions, distinguishing true progression from posttreatment effects, and predicting survival after 
radiotherapy, chemotherapy, and antiangiogenic treatments are presented.
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Introduction
Each year, over 250,000 primary brain and central nervous 
system cancers are diagnosed worldwide, 10% of which occur 
in North America.1 These types of cancer have 60% probability 
of death,2 and quality of life is often seriously diminished, even 
in treated patients.3 Gliomas, tumors derived from neuroglia, 
represent a majority of primary brain cancer cases. Based on 
their pathological features determined after biopsy, the World 
Health Organization (WHO) classifies gliomas into the 
following four grades: Grade I (low proliferative) and Grade 
II (infiltrative) are considered low-grade gliomas, whereas 
Grade III (histological evidence of malignancy) and Grade 
IV (cytologically malignant, mitotically active, and necrosis-
prone neoplasms) are high-grade gliomas.4,5 While low-grade 
gliomas may be managed with observation or surgery alone, 
higher grade tumors typically require multimodality treatment. 
Current strategies include maximum safe surgical resection 
followed by radiotherapy and chemotherapy.6 Although there 
is evidence that favorable outcome is associated with near-total 
resection of the tumor, a high-grade, malignant glioma often 
cannot be completely removed.7 Even with complete resection, 
rapid recurrence after surgery alone is common, and adjuvant 
radiotherapy is typically added to delay the time of recurrence. 
However, radiation toxicity to the surrounding normal tissue 
has to be minimized, and thus, the radiotherapy target tis-
sue volume often has to be restricted. Typically, the applied 
radiation field is optimized using three-dimensional confor-
mal radiotherapy,8 intensity-modulated radiotherapy,9 or ste-
reotactic surgery10 approaches. Such precision radiotherapy 
techniques require accurate tumor boundary delineation, 
typically on the basis of standard contrast-enhanced magnetic 
resonance (MR) imaging. Complementary functional imaging 
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information better identifies biologically significant tumor 
volumes (including quantitative perfusion and permeability 
surface data), enhances the treatment planning process,11 opti-
mizes treatment decision-making,12 and enables monitoring 
of the treatment13 noninvasively, resulting in improved patient 
care and treatment outcome.
The growing tumor. Neovascularization and necrosis are 
biologic hallmarks of malignant glioma that can potentially 
be interrogated through perfusion imaging. Tumor growth is 
dependent on the availability of an abundant supply of oxy-
gen and nutrients made possible by efficient blood flow (BF). 
In primary and metastatic brain tumors, the integrity of the 
blood–brain barrier (BBB) is compromised.14 The number 
of pericytes,15 astrocytes,16 and tight junction proteins17 are 
reduced, affecting the structural integrity and vascular func-
tion of BBB. In addition to BBB dysfunction, decreased tis-
sue oxygen concentration (hypoxia) is another characteristic of 
rapid tumor growth.18 Once the tumor has grown beyond the 
limit of oxygen diffusion (a few millimeters), the normal sup-
ply of blood cannot meet the oxygen demands caused by the 
elevated proliferative state of the tumor.19 To address this need, 
an adequate blood supply is provided through several mecha-
nisms including co-option, angiogenesis, and vasculogenesis.20 
These tissue perfusion and/or vessel permeability altering 
mechanisms are correlated with histopathologic changes and 
molecular markers related to tumor growth (eg, vascular endo-
thelial growth factor [VEGF]) and, therefore, could be used 
as a biomarker of tumor malignancy, margin, and invasion.21
Tumor identification and assessment. Histopathology 
remains the gold standard to identify and quantify the extent 
of a potentially malignant tumor; however, its application and 
ability to correctly define tumor grade is limited due to the 
invasive nature of the technique and potential sampling bias.22 
Tomographic (or cross-sectional) imaging-based techniques 
provide anatomical and functional information throughout 
the tumor, reducing sampling bias, and are minimally invasive.
The McDonald criteria23 is perhaps the most well-known 
metric to evaluate glioblastoma (GBM) treatment response. It 
uses the product of the maximal orthogonal diameters of the 
enhancing tumor on T1-weighted MR as a measure of tumor 
volume.23 With the introduction of new systemic therapy 
agents such as temozolomide and bevacizumab, novel patterns 
of imaging response such as pseudoprogression and pseudo-
response, reflecting treatment-related vascular changes, have 
emerged, requiring new imaging approaches to assess tumor 
response.24–26 The Response Assessment in Neuro-Oncology 
(RANO) group updated the McDonald criteria in 2010, and 
the revised document26 suggests that specific functional imag-
ing techniques, particularly perfusion and permeability, are 
needed to more appropriately characterize tumor progression 
and treatment response. Such information can be obtained 
from computed tomography (CT) or MR imaging, which 
acquire cross-sectional images that can define the location 
and size of the tumor. Of particular interest is extravasation 
of a contrast agent from the leaky BBB, as well as perfusion 
differences between the rim and core of the tumor. These 
concepts are described in detail in the following section.
Image-based Measurement of Perfusion 
and Permeability
A number of tomographic imaging techniques have been used 
for quantitative measurement of perfusion and permeability 
including MR-based (1) dynamic contrast-enhanced (DCE), 
(2) arterial spin labeling (ASL), and (3) dynamic susceptibil-
ity contrast (DSC) imaging, as well as (4) CT-based DCE 
imaging. All the approaches rely on endogenous (ASL) or 
exogenous agents (DSC, DCE). Exogenous agents are com-
monly termed contrast (agent) or tracer. For all techniques, 
quantitative maps are produced from the tomographic image 
data by applying the principles derived from indicator-dilution 
theory or kinetic modeling.24,25 The acquisition requirements 
for these approaches have been recently reviewed.27
Briefly, MR ASL selectively labels arterial blood (ie, it 
uses an endogenous tracer) in the neck and uses a subtraction 
imaging technique to assess BF in the brain tissue. ASL is a 
technology that is gaining interest in neuro-oncology,28 since 
it does not require the injection of exogenous contrast agent 
and does not use radiation. It has been proposed29 for assess-
ing tumors but is not widely used, though it may have a role 
in posttherapy surveillance imaging or in patients unable to 
receive exogenous contrast agents.27 The main challenges of 
the ASL technique include rapid T1 decay of the ASL mea-
surements, limiting investigation to where the flow is fast and 
lower signal-to-noise ratio and spatial resolution compared 
with DCE and DSC. Also, ASL cannot be performed after 
injection of T1 contrast agents.30 A number of different imple-
mentations of ASL are currently under assessment including 
continuous ASL, pulsed ASL, pseudocontinuous ASL, and 
velocity-selective ASL. Recently, a working group reviewed 
these emerging clinical techniques and published advice on 
the standardization of the ASL method, hopefully leading to 
improved clinical applications of this technique in future.31
MR DSC and DCE approaches are conceptually similar 
except that different MR acquisition techniques are used that 
cause the measured signal to either decrease or increase, respec-
tively, with increasing contrast agent concentration. In DSC 
approaches, depending on contrast agent concentration, a sus-
ceptibility gradient is generated between the tissue and the vas-
culature, which decreases the T2*-weighted signal.32 DSC MR 
technique is based on the assumptions that the contrast agent 
dilution in the blood is a function of BF and blood volume (BV) 
and that contrast agent remains intravascular (ie, does not leak 
into brain parenchyma) during imaging.32,33 Challenges when 
deriving quantitative maps from MR DSC data are numerous 
and principally derive from the nonlinear relationship between 
contrast agent concentration and measured signal, which lead 
to nonstationary noise characteristics34 and difficulties with 
partial volume correction.35 Also, any leakage of the contrast 
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agent to parenchymal tissue results in violation of the DSC MR 
assumption and can underestimate BV, particularly when con-
trast leakage is high, for example, due to damaged BBB as is 
common with brain tumors.36 Both ASL and DSC approaches 
are typically implemented using an echo-planar imaging 
sequence, which is sensitive to geometric distortions. Further-
more, MR ASL or DSC approaches cannot estimate perme-
ability directly. While there have been efforts to derive surrogate 
measures of permeability from DSC approaches, for example, 
relative recirculation,37 the validation of such efforts have been 
done using direct measurements from DCE approach.
Herein, we concentrate on CT and MR DCE tech-
niques, specifically focusing on their common features. These 
two approaches are also most commonly used for studying 
tumor perfusion and are the only MR and CT approaches that 
are able to estimate permeability. MR and CT DCE imaging 
characterizes tissue hemodynamics by tracking the passage of 
a bolus of contrast agent as it traverses through the microvas-
culature and brain parenchymal tissue. In both modalities, the 
passage of the contrast agent leads to a corresponding time-
course of signal enhancement that can be analyzed.
Kinetic modeling to quantify hemodynamics and BBB 
permeability surface. MR DCE analysis techniques consist 
of three main kinetic modeling steps, whereas the correspond-
ing CT analysis only requires the last step38:
1. Image signal intensity is converted to contrast agent con-
centration to obtain the time–concentration curve, Ct(t), 
of brain tissue or tumor,
2. Image signal intensity from an artery supplying the brain 
tissue is similarly converted to produce and estimate the 
arterial input function, Ca(t), and
3. An appropriate tracer kinetic model is then employed to 
calculate the hemodynamic parameters of interest, such as 
BF, BV, transit time, and permeability surface area prod-
uct (PS). (Parenthetically, similar modeling approaches 
can be used to analyze DSC MR data except for PS).27,39
Typically, tissue signals are obtained from all pixels in the 
brain, including the healthy tissue, so that maps of regional 
hemodynamic parameters can be obtained. The arterial 
input function is selected to best correspond to the time–
concentration curve of contrast agent entering the tissue(s) of 
interest. Key tracer kinetic parameters’ definitions are sum-
marized in Table 1.
The tissue time–concentration curve, Ct(t), can be mathe-
matically expressed as a convolution between the arterial input 
function and the blood flow-scaled impulse residue function, 
R(t) as explained in Ref. 24:
( ) ( ) ( ) ( ) ( )t a aC t BF C t R t C t BF R t= ⋅ ⊗ = ⊗ ⋅  (1)
After convolution, this yields an expression for the tissue 
time–concentration curve.
0
( ) ( ) [ ( )]
t
t aC t C t BF R t d= ⋅ ⋅ − τ τ∫  
The impulse residue function, R(t), describes the tissue 
time–concentration curve when the arterial input function 
is a delta impulse (ie, a nonphysiologic infinitely tall and 
narrow bolus), ie, 1 ( ).tBF δ  Empirically, the impulse resi-
due function is the fraction of contrast agent that remains 
in the tissue as a function of time after injection of an 
impulse contrast agent into the arterial input. By definition, 
max(R(t)) =  1 and the impulse residue function decreases 
monotonically from this maximum with increasing time. 
Also, R(t) = 0 for t  to, that is before the contrast arrives in 
the brain tissue at t = to.
Perfusion quantification. In practice, contrast agent is 
injected intravenously over a period of time (typically over 
15–25 seconds for CT, 10 seconds for MR), such that the 
arterial input function, Ca(t), is not an impulse, but rather dis-
tributed over a finite duration. Provided that the image sig-
nal varies linearly with concentration (as is the case for CT 
and MR DCE) and BF is constant within the period of mea-
surement, the tissue time–concentration curve, Ct(t), can be 
estimated by the convolution of the arterial input function, 
Ca(t), and the impulse residue function, R(t), using the math-
ematical principle of linear superposition, ie, using Eq (1).24 
Total DCE data acquisition duration is normally less than two 
minutes if only perfusion parameter estimates are required by 
deconvolution of Eq (1).24,40 From the deconvolved impulse 
residue function, BF equals to the maximum of the impulse 
residue function, while BV can be estimated from the area 
under the curve of the tissue time–concentration curve as 
discussed by Lee et al.24 An acquisition temporal resolution 
of one to two seconds is typically required to produce per-
fusion maps.41
A commonly used semiquantitative parameter in brain 
cancer imaging is the normalized BV (nBV). The nBV is 
defined as the BV in the tumor divided by the BV in the same 
volume of normal contralateral brain. Peak height (PH) is 
another semiquantitative measure defined as the maximum 
contrast enhancement from the baseline signal during the first 
pass of contrast agent. Normalized blood flow (nBF) and nor-
malized peak height (nPH) of the tumor are defined similar 
to nBV.
Permeability quantification. If the permeability parameter 
estimates are of interest (eg, the rate of extravasation of con-
trast agent from the intravascular space into the extravascular 
extracellular space (EES) as assessed by PS or Ktrans), then 
tomographic imaging data must be collected for longer peri-
ods, typically for between three and six minutes.40 Kinetic 
models are required to quantify perfusion and permeabil-
ity parameters.42 The different kinetic models include the 
following: (1) model-independent approaches for BF mea-
surements based on the Fick principle and deconvolution 
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analysis; (2) compartmental modeling, as exemplified by 
the Patlak model;43 or (3) modeling that accounts for con-
vective transport (BF) and bidirectional diffusion exchange 
(capillary permeability) via a distributed parameter model, 
eg, the Johnson–Wilson model.44 Both compartmental and 
distributed parameter models have been used to calculate 
kinetic parameters including BF, BV, and PS from DCE 
images.
Here, we focus on the Johnson–Wilson model,44 in 
particular, its modification by St Lawrence and Lee.45 The 
modified Johnson–Wilson model is a more physiologically 
realistic distributed parameter model and allows the simul-
taneous determination of BF, BV, and PS. The modified 
Johnson–Wilson model has a closed-form solution to the 
impulse residue function R(t).45 R(t) is defined as:
1 0
( ) ,
e
BF E BVtv BF
BVt BFR t
BVEe t BF
⋅  
− −  
   
=     
 

 
(2)
where the extraction fraction E is defined as:
1 .
PS
BFE e= −  (3)
Schematic representation of the Johnson–Wilson model, 
as well as the modifications due to St Lawrence and Lee, is 
presented in Figure 1. These distributed parameter models 
enable the separation of BF and E, thus allowing for the cal-
culation of the PS area product. The Johnson–Wilson model 
achieves this by modeling convection along the vessel as a 
constant flow velocity.24
For the modified Johnson–Wilson model, Eqs (1) and (2) 
lead to the following for the tissue curve, Ct(t):
−
= ⋅ + ∫
trans
( )
trans
0
( ) ( ) ( ) e
Kt t uv
t a aC t BV C t K C u e du
 
(4)
where ve is the volume of EES per unit volume of tissue 
and Ktrans is the flow extraction product (BV⋅E). From the 
Table 1. Glossary of perfusion and permeability imaging parameters.
TERM SYMBOL DEFINITION
Blood flow BF Flow rate of the blood per unit mass or volume of tissue (ml.min.100 g-1 or ml⋅min.100 ml-1).
Blood volume BV Volume of flowing blood within vasculature per unit mass or volume of tissue (ml.100 g-1 
or ml.100 ml-1).
extraction fraction E Fraction of the contrast that extravasates from intravascular space into extravascular space 
within the first pass through the vasculature.
initial aUC iaUC a semi-quantitative measure of contrast enhancement used in DCe mr. it is related to dose 
of contrast injected, the blood volume, and blood–brain barrier permeability surface product.
mean aUCrH maUCrH The ratio between iAUC and the final AUC from a DCE MR scan gives AUCR. If the histo-
gram of aUCr of a region is bimodal or skewed, the mean for higher peak of this distribution 
is calculated to give the maUCrH.
mean transit time mTT average time(s) for blood to traverse from arterial to the venous end of the vasculature.
normalized BF nBF BF of a region of interest normalized to the contralateral normal brain.
normalized BV nBV BV of a region of interest normalized to the contralateral normal brain.
normalized maximum slope – a semi-quantitative estimation of BF. it is the maximum slope of a tissue time-contrast 
enhancement curve normalized by the maximum of the arterial time-contrast enhancement 
curve.
Peak height PH A measure of maximum contrast enhancement from the baseline signal during the first pass 
of contrast.
normalized peak height nPH PH of the tumor can be normalized to the contralateral normal brain to give the normalized 
peak height.
Permeability – Unidirectional flux rate of contrast agent from the blood plasma into the brain parenchyma 
(ie, interstitial space) normalized by the total surface area of capillaries per unit mass of 
tissue. it is often estimated using the parameters permeability-surface area product (Ps) 
and transfer rate constant (Ktrans).
Permeability surface area product Ps Product of permeability and total surface area of capillaries per unit mass of tissue 
(ml.min.100 g-1).
Efflux rate constant kep Rate constant of contrast efflux rate from the brain parenchyma back into the blood plasma 
(min-1).
Transfer constant Ktrans Flow rate constant of contrast from the blood plasma to the brain parenchyma (min-1).
Vp Vp Volume of flowing blood within the vasculature per unit mass or volume of tissue (ml.100 g-1 
or dimensionless).
extravascular volume ve Volume of extracellular space per unit volume of tissue for contrast to distribute into 
(ml.100 g-1 or dimensionless).
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definition of E [Eq (3)], in the limit of PS =  F, which is 
the case for brain tumors, Ktrans ~  PS. A temporal resolu-
tion of 5–10 seconds per image is commonly used to balance 
the competing spatial resolution, scan coverage, and signal-
to-noise ratio requirements when assessing permeability, 
but this acquisition rate is too slow for the measurements 
of BF and BV where a finer temporal resolution (1–2 sec-
onds) is required.41 While there is no consensus as to which 
CT acquisition technique is optimal for both perfusion and 
permeability quantitation,46 acquisition techniques with dif-
ferent temporal resolutions, including initial high temporal 
resolution for perfusion measurement followed by lower tem-
poral resolution acquisition for permeability measurement, 
are suggested to provide useful measurements and lowered 
radiation dose.47
Differences between CT- and MR-based DCE. 
While a similar analysis framework (ie, distributed param-
eter model) can be used to process DCE data acquired by CT 
or MR imaging, there are some notable differences between 
these modalities that need be discussed. First, the inherent 
image contrast mechanisms are different: CT DCE imag-
ing measures contrast agent concentration, resulting from 
the changes in X-ray attenuation coefficient. MR DCE tech-
niques measure the contrast agent concentration indirectly via 
the effect on the T1 relaxation rate on nearby water protons 
in the tissue. In MR DCE imaging, as previously described, 
additional kinetic modeling steps are required to convert 
from measured MR signal intensity to tracer concentration. 
CT contrast agent is iodine based,48 while MR is gadolinium 
based.39 Comparison of tumor parametric maps derived by 
DCE-CT and MR are reported to have consistent findings.49 
A close correlation of independently derived quantitative 
parameters from DCE-CT and MR indicates that both are 
measuring the same underlying tumor physiology.49 Table 2 
summarizes and compares the key aspects of DCE-MR and 
DCE-CT.
DCE-CT perfusion and permeability imaging—implemen-
tation details. DCE-CT refers to the acquisition of serial CT 
images to track the passage of a bolus of iodinated contrast 
agent. The typical DCE-CT protocol takes 2–3 minutes, and 
it involves rapid acquisition of images (1–2 seconds per image) 
during the initial phase of imaging (45 seconds) to capture the 
first pass of contrast agent for the calculation of BF and BV. 
To decrease the radiation dose, the second phase that involves 
less-frequent acquisition (10–15-second image interval) is 
required to calculate PS or Ktrans.24
The clinical use of DCE-CT was initially slow to 
develop due to its relatively limited scan volume (2–4  cm 
coverage) and associated radiation dose (2–5 mSv).40 Larger 
multirow detector technology now allows for the coverage 
of 16 cm of the anatomy.50 Shuttle mode imaging can also 
increase the scan coverage.51 More advanced reconstruction 
methods, such as adaptive statistical iterative reconstruction 
technique,52 and reducing the temporal resolution of image 
acquisition (3 seconds) in the first phase53 have both been 
demonstrated as effective ways to reduce the dose. Figure 2 
shows an example for CT DCE perfusion and permeabil-
ity images obtained in an anaplastic oligodendroglioma 
patient.
DCE-MR perfusion and permeability imaging—imple-
mentation details. DCE-MR refers to the acquisition of serial 
MR images using a T1-weighted sequence. The increase in 
T1 relaxation rate from the corresponding increases in con-
trast agent concentration results in an increase in MR signal 
intensity. DCE-MR scan duration is normally less than two 
minutes, but scans from three to six minutes are required if 
the rate of extravasation of contrast agent from the intravas-
cular space into the EES (ie, PS or Ktrans) is to be measured. 
Typically, the whole brain is acquired at a temporal acquisition 
rate of an image volume every two seconds. Recent techniques 
such as multichannel parallel imaging, multislice imaging, 
and compressed sensing can preserve whole-brain coverage 
and achieve finer temporal resolution.54 Figure 3 provides an 
example for MR DCE perfusion and permeability images 
for a postresection GBM patient showing normal-appearing 
parenchyma and recurrent tumor.
Figure 1. (A) Schematic drawing of the modified Johnson–Wilson model,44 
where the central cylinder represents all the vessels in the tissue region 
and the annulus around the cylinder is the interstitial space into or out of 
which contrast can diffuse. The interstitial space is assumed to be a well-
stirred compartment, such that contrast concentration, Ce(t) is uniformly 
distributed at any time. in the blood vessels, contrast concentration Cb(x,t) 
changes with axial position (x) with respect to the arterial end as contrast 
diffuse into the interstitial space at a rate equal to the permeability surface 
product (Ps). after the contrast bolus exits from the vessels, contrast in 
the interstitial space diffuses back into the vessels also at the rate of Ps. 
F is the blood flow, Ca(t) and Cv(t) are the arterial and venous contrast 
concentrations, respectively, and Vb and Ve are the blood and interstitial 
volumes, respectively. (B) Flow-scaled impulse residue function [R(t)] 
of the modified Johnson–Wilson model for a tissue with BF, BF = 60 mL 
minute-1 (100 g-1, Vb = 8.4 mL (100 g)-1, vascular mean transit time 
14 seconds, and Ps = 21.4 mL minute-1 (100 g)-1.
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Applications of Perfusion and Permeability 
Biomarkers in Brain Cancer
Multiple applications for perfusion and permeability imaging 
of brain tumors have been explored to enhance the treatment 
planning process, to optimize treatment decision-making, to 
enable treatment monitoring, and to assess prognosis. In this 
section, we selectively target and review three key applica-
tions: differentiating malignant brain lesions, distinguishing 
true progression from posttreatment effects, and predicting 
survival after treatment therapies.
Differentiation of malignant brain lesions. Solitary 
brain metastases with no history of primary cancer are 
found in approximately 15% of patients and may have simi-
lar imaging features to primary malignant gliomas on con-
ventional MR images.55 Two factors should be considered 
when using perfusion imaging to differentiate solitary brain 
Table 2. Comparison of mr and CT DCe techniques.
PARAMETER MR DCE CT DCE
source of signal Decrease in T1 of surrounding water molecules attenuation of x-ray by iodinated contrast
Change in signal intensity signal gain—assumed proportional to increasing 
contrast agent concentration
signal gain—assumed proportional to increasing 
contrast agent concentration
Tracer kinetic analysis method Compartmental model and distributed parameter 
models
Compartmental and distributed parameter models
Quantitative techniques relative and absolute relative and absolute
Typical scan coverage Close to whole brain 4 cm, 8 cm, and 16 cm coverage with multidetector 
CT system
Typical temporal resolution 5 s to 10 s First phase: 1 s to 2 s
second phase: 5 s for Patlak model43 and 10 s 
to 15 s for Johnson and Wilson model44
Typical scan duration, perfusion only 90 s 45 s
Typical scan duration, perfusion and 
permeability
5 min to 10 min 2 min to 3 min
representative contrast agent Gadopentetate dimeglumine iopamidol
molecular weight of representative 
contrast agent
938 g/mol (0.938 kDa) 777 g/mol (0.777 kDa)
 ??????
?????? ?? ?? ??
??????????? ????? ?? ???????????????? ???????????????????????????? ????? ?? ?? ?? ?????? ???????????????????????
Figure 2. CT Perfusion technique in a patient with an anaplastic oligodendroglioma, prior to subtotal resection of the tumor. a series of images were 
acquired with contrast injection. In the top row of the figure, the artery region (blue line in the left panel), normal (green region in the central panel in the 
top row), and tumor (purple line in the central panel in top row) are shown in a CT image at peak enhancement and in a baseline CT image before contrast 
arrival. The corresponding background subtracted time–density curves (normalized to the same maximum) are also shown using the same color-coding 
scheme. In the bottom row of the figure, the time-averaged CT image, BF, BV, and PS maps in the same CT slice as in the top row are shown. White 
arrows point to the tumor in the different images and functional maps.
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metastases from malignant gliomas. First, current evidence 
suggests that BV in the contrast-enhancing metastatic lesion 
depends on the primary tumor site.56 Metastases from mela-
noma and renal carcinoma, for example, are reported to have 
higher BV than malignant gliomas.57 Studies that considered 
different sites of origin as one entity (or those that did not 
report primary tumor) showed that the BV of the enhanc-
ing metastatic lesions was either similar58,59 or lower60,61 
than the malignant gliomas. Together, these studies suggest 
that the differentiation of brain metastasis from malignant 
glioma based on the BV of the contrast-enhancing lesion 
alone is challenging. Second, BV in the nonenhancing lesion 
shows promise for distinguishing metastases from primary 
malignant gliomas. For example, on CT or MR imaging, a 
low-intensity region (CT, T1 MR) or high-intensity lesion 
(T2 MR) around an enhancing lesion may represent edema 
or infiltrating tumor or a combination of both. In the case 
of metastases, infiltration more than 1–2  mm beyond the 
enhancing tumor is rare62 so this region most often repre-
sents edema, while in malignant glioma, infiltration 1–2 cm 
is not uncommon. The high BV in the nonenhancing malig-
nant glioma lesion can be attributed to their aggressive and 
infiltrative growth, which often extends into the surrounding 
T2-hyperintense region. The median sensitivity and speci-
ficity for distinguishing between nonenhancing lesions and 
gliomas using BV were 90% (range: 77%–100%) and 95% 
(64%–100%), respectively.60,61,63 In contrast, the median 
sensitivity and specificity for contrast-enhancing lesions’ vs 
gliomas’ nBV (see definition in Table 1) were 87% (80%–91%) 
and 72% (64%–88%), respectively.63,64
Perfusion imaging can also differentiate malignant glio-
mas (Grades III and IV) from other primary brain tumors. 
These include differentiating primary malignant gliomas from 
lymphomas,65,66 meningiomas,67 hemangioblastomas,67 and 
schwannomas.67 Some studies have used perfusion imaging to 
differentiate subtypes of primary brain tumors.68,69 Grade II 
and III oligodendroglial tumors showed higher nBV than both 
Grade II and III oligoastrocytic and astrocytic tumors, and 
oligoastrocytic tumors showed higher maximum nBV than 
astrocytic tumours.70 A sensitivity and specificity of 100% and 
88%, respectively, were found when nBV was used to differen-
tiate Grade II and III oligodendroglial tumors from astrocytic 
tumors. Although there were differences in BV between the 
different types of primary brain tumors, the number of brain 
tumor types make this method of differentiation impractical.
Perfusion can help distinguish between high-and low-
grade gliomas.71 High-grade gliomas, particularly Grade IV, 
are highly infiltrative tumors with recurrence typically aris-
ing within 2 cm of the irradiated volume.72 An active area of 
study is to evaluate the prognostic value of perfusion imag-
ing for predicting the overall survival of patients with high-
grade gliomas. An example of presurgery CT perfusion and 
MR images of two high-grade glioma patients is shown in 
Figure 4.
It is important to note that differentiation of tumor grade 
in oligodendroglial tumors based solely on perfusion imaging 
????? ????????????????????????????????? ?? ??????????????? ?? ?? ???????????????? ????????????? ???????? ?????
Figure 3. mr DCe technique in a GBm patient postresection. analogous to CT DCe example (Fig. 2), a series of pre- and postcontrast agent injection 
images are acquired to measure contrast concentration over time (see text) in order to derive contrast agent vs time–concentration curves and parameter 
maps, such as cerebral BF, cerebral BV, and PS using the modified Johnson–Wilson model. White arrows point to the recurrent tumor.
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should be interpreted with some caution since there is evidence 
that oligodendroglial tumors can have higher BV than astro-
cytic tumors, irrespective of the tumor grade.70 However, high-
grade oligodendroglial tumors may or may not have higher BV 
than low-grade oligodendroglial tumors.70,73 Therefore, per-
fusion imaging-based assessment of oligodendroglial tumors 
should be considered separately from astrocytic tumors, and 
perfusion imaging alone does not seem to provide a reliable 
criterion for differentiating oligodendroglial tumor grade.
Differentiation of progression from posttreatment 
effects. A change in the size of the contrast-enhancing tumor 
is used as a radiologic measure of progression, but it can be 
confounded by other sources of contrast enhancement. Pseu-
doprogression and treatment-induced necrosis (TIN) are 
posttreatment scenarios with a better prognosis than true pro-
gression, but their changes in contrast enhancement pattern 
can be indistinguishable from tumor progression.74 Erroneous 
diagnosis of pseudoprogression or TIN as tumor progression 
can lead to unnecessary treatment or premature abandonment 
of treatment. Interpreting progression incorrectly may delay 
the treatment.
Pseudoprogression occurs in 20%–30% of malignant 
glioma patients treated with chemoirradiation and manifests 
as a transient increase in tumor contrast enhancement at one 
to three months posttreatment that eventually subsides.75,76 
Although its pathophysiology remains unclear, chemoirra-
diation is believed to induce a transient local inflammatory 
reaction, edema, and increased vessel permeability, which 
manifests as increased signal on contrast-enhanced images.77 
Also, radiation injury can induce an increase of VEGF, which 
can subsequently lead to perfusion increase. However, there is 
evidence that when using DSC MR perfusion imaging, true 
progression had a higher maximum nBV than pseudoprogres-
sion when confirmed by radiologic and clinical follow-ups (sen-
sitivity and specificity of 81.5% and 77.8%, respectively).76,78 
Another study showed that both nBV and nPH could dis-
tinguish pseudoprogression from progression with sensitivi-
ties and specificities of both 75%.79 Histogram analysis of 
nBV to characterize percent changes in nBV skewness and 
kurtosis is also a potential biomarker for differentiating pseu-
doprogression from true progression.80 In another prospective 
study, a decrease in nBV after three weeks of chemoirradia-
tion was associated with a higher risk of early progression.75 
Also, TIN occurs 3–12 months after radiotherapy in 3%–24% 
of patients.77 Radiation-induced necrosis and pseudoprogres-
sion were collectively defined as radiation-induced injury in 
eight MR perfusion studies.81 Mean and maximum nBV were 
reported to differentiate radiation-induced injury from true 
progression with sensitivities and specificities ranging from 
86% to 100% and 80% to 100%, respectively.82,83 Radiation-
induced injury and true progression often coexist in patients. 
Hu et al showed that MR perfusion imaging was able to esti-
mate the fractional tumor burden (ie, progression) and post-
treatment effect (ie, radiation-induced injury) within the same 
MR contrast-enhancing lesion.84 This fractional tumor bur-
den strongly correlated with the histological tumor fraction 
obtained from stereotactic biopsy (r = 0.82, P  0.001) and 
correlated with the overall survival (P  0.02). These results 
demonstrate that MR may be a useful clinical tool to differen-
tiate progression from posttreatment effects.
Survival after radiotherapy and chemotherapy. The 
value of perfusion imaging in predicting progression-free 
????????? ????????????? ????????????? ?????? ????????? ?????? ??????????????????????????????
Figure 4. illustrative presurgery CT perfusion and mr images of two patients both with Grade iV gliomas. Both patients presented with a contrast-
enhancing lesion on postgadolinium T1-weighted mr images, which also had elevated BF, BV, and Ps. Patient a presented with low BF, BV, and Ps in the 
nonenhancing lesion (neL, asterisk). Patient B presented with regions of elevated BF, BV, and Ps in the neL (red arrows). The survival for patient a was 
41.6 months and patient B was 16.7 months. Color bar scale for maps is as follows: 10–75 mL minute-1 (100 g)-1 for BF, 0.5–10 mL (100 g)-1 for BV, and 
1–10 mL minute-1 (100 g)-1 for PS. This figure was reproduced from Ref. 98 with the permission of the copyright holder.
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survival (PFS) and overall survival has been investigated in 
numerous studies. The interpretation of perfusion imaging 
data for predictive survival depends on treatment regimen 
and imaging schedule. Three perfusion imaging schedules 
for predicting outcomes have been reported as follows: (1) 
pretreatment, (2) pretreatment and midtreatment, and (3) 
pretreatment and posttreatment. Figure 5 shows an exam-
ple of perfusion and permeability surface maps at prera-
diotherapy, near-end-of-radiotherapy, and with tumor 
progression.
When pre-chemoirradiation MR perfusion images were 
considered, a higher mean and maximum nBV were associ-
ated with poor PFS and lower overall survival for gliomas of 
all grades.85–87 The two-year overall survival rate for Grade III 
astrocytomas was significantly lower for patients with maxi-
mum nBV  2.3 (33% vs 100%, P  0.01), and it was also 
lower for GBM (5% vs 25%, P = 0.013).85 Using DCE-CT 
imaging, a combination of high BV and PS was associated 
with poor overall survival for Grade III and IV gliomas and 
for Grade IV gliomas alone.88,89 In patients with GBM, 
kep values   1.2 minute-1, between 1.21 and 2.0 minute-1, 
and 2.0 minute-1 had one-year overall survival rate of 59%, 
33%, and 15%, respectively (P value not reported).90 These 
studies suggest that pretreatment higher BV, higher PS, and 
higher kep were associated with more aggressive phenotypes 
that conferred poor survival.
The prognostic value of comparing pre- and midra-
diotherapy perfusion imaging parameters has been investi-
gated.91,92 Based on the parametric response map analysis, a 
decrease in tumor BV and BF at one and three weeks into 
chemoirradiation were predictive of poor overall survival.91,92 
Specifically, patients with 6.8% of tumor volume, showing 
a decrease in nBV, had reduced overall survival than those 
with 6.8% of tumor volume, showing a decrease in nBV 
(median overall survival of 7.1 and 20.4 months, respec-
tively; P = 0.001).91 A drop in BV during treatment suggests 
increased tumor hypoxia, leading to chemoirradiation resis-
tance. These studies suggest that BF and BV measurements 
can potentially identify the patients with poor survival even 
before the completion of chemoirradiation.??????????????????????????
????????? ???? ??
???????????????????????????????????????? ?????????????????
Figure 5. Preradiotherapy gross tumor (T1-weighted mr), near-end-of radiotherapy enhancing lesion (averaged CT), and progressive tumor (T1-weighted 
mr); and the corresponding parametric maps of BF, BV, Ps, standard uptake value (sUV), and sUV:BF ratio acquired using CT perfusion and FDG-PeT. 
Blue outlines show the contrast-enhancing lesions delineated by a radiation oncologist. Yellow outline is the 2 cm bounding box that was set for performing 
analysis of neighboring pixels. This figure originally appeared in the Journal of Medical Radiation Sciences, 2014;61:4–13 and was reproduced under 
terms of the Creative Commons attribution License with the permission of the copyright holder.110
Abbreviations: MR, magnetic resonance; CT, computed tomography; FDG-PET, 18-fluorodeoxyglucose positron emission tomography. 
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Tumor perfusion after the completion of chemoir-
radiation and its association with survival have also been 
investigated.93,94 An increase in the maximum nBF between 
baseline and follow-up imaging was a better prognosticator 
of shorter PFS (hazard ratio [HR] =  2.67, P =  0.010) than 
an increase in tumor diameter (HR = 1.14, P = 0.049).95 At 
one-month postradiotherapy, Mangla et al showed that 
an increase in nBV was predictive of poor one-year overall 
survival (sensitivity = 90% and specificity = 69%), while the 
tumor size was not.96 However, another study showed that 
perfusion imaging was not predictive of survival, while tumor 
diameters by T1- and T2-weighted imaging were predictive.93 
Using ferumoxytol (an iron-based MR contrast agent) postra-
diotherapy, lower tumor nBV predicted patients with longer 
overall survival (P   0.001).97 In the nonenhancing lesion, 
Li et al showed that a higher median nBV immediately after 
radiation was associated with shorter PFS (P  =  0.026).94 
Finally, Yeung et al98 showed higher trends in BF, BV, and 
PS in the contrast-enhancing lesions and the nonenhancing 
lesions in patients with OS  18 months compared with those 
with OS  18 months.
In summary, a high BV before and after chemoirradia-
tion and a decrease in BV during chemoirradiation are associ-
ated with poor survival. A high BV before and after treatment 
is characteristic of tumor growth and progression, while a 
decrease in BV during treatment may be indicative of tumor 
hypoxia.
Survival after antiangiogenic therapy. Radiologic assess-
ment of response to antiangiogenic agents, especially those that 
target VEGF, should be interpreted with caution because a 
decrease in contrast enhancement is not necessarily indicative 
of true response (ie, it may be a pseudoresponse).26 Batchelor 
et al99 showed that patients treated with cediranib demonstrated 
decreased MR signal enhancement as early as one day after the 
initiation of treatment, despite considerable variability in tumor 
response. Given the vascular effects of antiangiogenic agents, 
DCE perfusion imaging may potentially play an important role 
in providing insight and assessing response to these agents.
For recurrent GBMs, high nBV and Ktrans prior to anti-
VEGF monotherapy or in combination with temozolomide 
were associated with poor survival. Tumor BF,99 nBV,99,100 
Ktrans,101 and ve102 decreased shortly after the initiation of 
bevacizumab or cediranib. In the nonenhancing lesions, nBV 
could also decrease after bevacizumab treatment, suggesting 
that the drug may have an antiedema effect (statistical sig-
nificance not reported).103 There is no consensus on whether 
a decrease in these parameters is a positive prognosticator. 
A decrease in Ktrans and nBV after bevacizumab treatment 
did not show a significant association with PFS or overall 
survival in some studies.104 In another study, a decrease in 
tumor subvolume with nBV  1.00 after bevacizumab treat-
ment was associated with longer time to progression.105 
A reduction in Ktrans after cediranib treatment was associ-
ated with improved PFS and OS.106 A moderate correlation 
(Spearman’s ρ = 0.58, P = 0.036) between overall survival and 
Ktrans at one week after stereotactic radiosurgery and beva-
cizumab was reported in patients with recurrent malignant 
gliomas.107
The inconsistent relationships found between various 
perfusion and permeability imaging parameters and overall 
survival suggest that not all patients responded equally to anti-
angiogenic agents. Sorensen et al showed that 25% of patients 
with recurrent GBMs treated with cediranib exhibited ele-
vated perfusion, and these patients had higher PFS and over-
all survival than those with stable or decreased perfusion.106 
This finding was confirmed in patients with newly diagnosed 
gliblastomas that were treated with radiotherapy, temozolo-
mide, and cediranib. Patients with increased perfusion had 
a significantly longer median overall survival than patients 
with decreased perfusion (overall survival of 504 vs 321 days; 
log-rank P  0.05).103 Increased perfusion was also associated 
with improved tumor oxygenation, which could potentially 
improve the sensitization of tumor cells to chemoirradiation 
and enhance the delivery of temozolomide to the tumor. In 
a study involving patients with recurrent malignant gliomas, 
independent component analysis of MR perfusion images was 
used to characterize the extent of abnormal vasculature before 
and after bevacizumab treatment. A decrease in the arteriove-
nous overlap (ie, a decrease of abnormal vasculature) was asso-
ciated with longer overall survival in these patients (P  0.04), 
whereas a change in the tumor volume and nBV was not pre-
dictive of overall survival.108 In aggregate, these results sug-
gest that perfusion imaging may be a tool for selecting the 
appropriate patients for antiangiogenic therapies. More pro-
spective information preferably gathered at multiple centers 
with high quality control is needed to clarify the reported het-
erogeneities in results.109
Summary
We provided an overview of DCE-CT and MR perfusion 
and permeability principles, parameters, and applications in 
brain cancer. These perfusion and permeability quantification 
approaches may serve as potential biomarkers for differentia-
tion of malignant lesions and posttreatment effects and for 
investigations on survival after radiotherapy, chemotherapy, 
and antiangiogenic treatments.
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